Search | Clinical Trials Finder

Conditions: Hepatitis C, Chronic
Interventions: GS-6620, GS-6620 tablet, 450 mg BID, GS-6620 tablet; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 12
States / cities: Anaheim, California • Los Angeles, California • DeLand, Florida + 8 more

Conditions: Recreational Drug Use
Interventions: PF614, Oxycodone Hydrochloride 40 mg, Placebo; Drug
Lead sponsor: Ensysce Biosciences; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Diabetic Foot Infections
Interventions: Bisphosphocin Nu-3, Placebo; Drug
Lead sponsor: Lakewood-Amedex Inc; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 3
States / cities: San Francisco, California • Oldsmar, Florida • Franklin, Tennessee

Conditions: Opioid Dependence, Opioid Related Disorders, Cocaine Dependence
Interventions: RBP-8000 100 mg, Placebo, Cocaine, RBP-8000 200 mg; Drug
Lead sponsor: Indivior Inc.; Industry
Eligibility: 21 Years to 50 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Healthy
Interventions: Odalasvir 100 mg, Placebo, Odalasvir 500 mg, Odalasvir (Up to maximum 1000 mg); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Inflammation, Fatigue
Interventions: Riluzole, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 21 Years to 65 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Glycemic Control
Interventions: Fasiglifam (TAK-875), Sitagliptin, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 916 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 58
States / cities: Muscle Shoals, Alabama • Mesa, Arizona • Peoria, Arizona + 55 more

Conditions: Chronic Refractory Cough
Interventions: BLU-5937, Placebo; Drug
Lead sponsor: Bellus Health Inc. - a GSK company; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 8
States / cities: San Diego, California • San Jose, California • Largo, Florida + 5 more

Conditions: Schizophrenia
Interventions: Placebo, Paliperidone Palmitate; Drug
Lead sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 414 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 18
States / cities: Little Rock, Arkansas • Cerritos, California • Santa Ana, California + 15 more

Conditions: Hypercholesterolemia
Interventions: Lapaquistat acetate and atorvastatin, Atorvastatin; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 448 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 78
States / cities: Birmingham, Alabama • Northport, Alabama • Sierra Vista, Arizona + 75 more

Conditions: Generalized Anxiety Disorder
Interventions: sertraline 50 mg daily, sertraline 100 mg daily, Placebo 50 or 100 mg; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 60 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 3
States / cities: Tuscaloosa, Alabama • Miami, Florida • Charleston, South Carolina

Conditions: Thrombocytopaenia
Interventions: eltrombopag, placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 110 Years
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 18
States / cities: Phoenix, Arizona • Hot Springs, Arkansas • Jonesboro, Arkansas + 15 more

Conditions: Idiopathic Parkinson's Disease
Interventions: Safinimide 50-100 mg/day, Matching Placebo; Drug
Lead sponsor: Newron Pharmaceuticals SPA; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 549 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 28
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 24 more

Conditions: Prostate Cancer
Interventions: Thalidomide, leuprolide acetate, goserelin, Placebo; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Male only
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2010
U.S. locations: 9
States / cities: Fort Lauderdale, Florida • New Orleans, Louisiana • Bethesda, Maryland + 6 more

Conditions: Alzheimer's Disease
Interventions: E2609, Placebo for E2609; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Glendale, California • Baltimore, Maryland

Conditions: Non-alcoholic Fatty Liver Disease, Obesity
Interventions: BI 3006337, Placebo matching BI 3006337; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 12
States / cities: Chula Vista, California • La Mesa, California • Montclair, California + 8 more

Conditions: Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: ibrutinib, venetoclax, Placebo; Drug
Lead sponsor: Pharmacyclics LLC.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2024
U.S. locations: 14
States / cities: Duarte, California • La Jolla, California • Orange, California + 11 more

Conditions: Alzheimer's Disease
Interventions: SUVN-502, Placebo, Donepezil, Memantine; Drug
Lead sponsor: Suven Life Sciences Limited; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 564 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 71
States / cities: Phoenix, Arizona • Tucson, Arizona • Costa Mesa, California + 56 more

Conditions: Pharmacokinetics
Interventions: Nafamostat Mesilate, Placebo; Drug
Lead sponsor: Ensysce Biosciences; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Healthy, Botulinum Toxin
Interventions: G03-52-01, Placebo; Drug
Lead sponsor: U.S. Army Medical Research and Development Command; Federal
Eligibility: 18 Years to 65 Years
Enrollment: 622 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 15
States / cities: Mobile, Alabama • Tempe, Arizona • Fort Myers, Florida + 11 more

Conditions: Major Depressive Disorder
Interventions: mixed salts amphetamine; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Rheumatoid Arthritis
Interventions: IDEC-C2B8 (rituximab), Placebo, Methotrexate, Etanercept, Adalimumab, Methylprednisolone, Folate; Biological · Drug · Dietary Supplement
Lead sponsor: Biogen; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 18
States / cities: Huntsville, Alabama • Paradise Valley, Arizona • Palm Desert, California + 15 more

Conditions: Erectile Dysfunction, Testosterone Deficiency, Diabetes
Interventions: Sildenafil citrate (open label), Testosterone gel, Placebo gel; Drug · Other
Lead sponsor: Boston University; Other
Eligibility: 40 Years to 70 Years · Male only
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Gaucher Disease, Type 1
Interventions: Eliglustat tartrate, Placebo; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 16 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 6
States / cities: San Francisco, California • New Haven, Connecticut • Decatur, Georgia + 2 more

Search by objective public record fields.

A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-6620 in Treatment Naïve Subjects With Chronic Hepatitis C Virus Infection

A Study to Evaluate the Oral Abuse Potential of PF614 in Non-Dependent Recreational Opioid Users (PF614-104)

Topically Applied Bisphosphocin Nu-3 on Infected Diabetic Ulcers of Subjects With Type I or II Diabetes Mellitus

A Randomized, 4-sequence, 2-period, Double-blind, Placebo Controlled Study With a DSM-IV-TR Diagnosis of Cocaine Abuse

A Study to Evaluate the Pharmacokinetics and the Effect on Cardiac Repolarization of Odalasvir Administered as a Single Dose Tablet Under Fed Conditions in Healthy Participants

Effects of Riluzole on CNS Glutamate and Fatigue in Breast Cancer Survivors With High Inflammation

Comparison of Fasiglifam (TAK-875) to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes

A Dose Escalation Study of BLU-5937 in Unexplained or Refractory Chronic Cough

A Study of the Efficacy (Effectiveness) of Paliperidone Palmitate in the Prevention of Recurrence of the Symptoms of Schizophrenia.

Efficacy of Lapaquistat Acetate and Atorvastatin on Blood Cholesterol Levels in Subjects With Primary Hypercholesterolemia

Pharmacological Treatment of Generalized Anxiety Disorder in the Elderly

A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia

Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa

Thalidomide for the Treatment of Hormone-Dependent Prostate Cancer

Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02)

A Study to Test How Well Different Doses of BI 3006337 Are Tolerated by People With Overweight or Obesity and With Fatty Liver Disease

Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)

SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study

Oral Nafamostat in Healthy Volunteers (NAF-101)

Single or Repeat Dose of G03-52-01 in Adult Subjects

Adjunctive Mixed Salts Amphetamine for Depressed Adults With Incomplete Response to Current Antidepressant Therapy

Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis

Effect of Testosterone in Men With Erectile Dysfunction

A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease (ENGAGE)